Could a daily pill replace chemo for some breast cancer patients?
NCT ID NCT07615751
First seen Jun 04, 2026 · Last updated Jun 12, 2026 · Updated 2 times
Summary
This phase 3 study compares an all-oral, chemotherapy-free drug combination (pyrotinib, trastuzumab subcutaneous, and dalpiciclib) against a standard chemo-containing regimen for advanced HER2-positive breast cancer. About 502 adults who have had at most one prior treatment for advanced disease will participate. The goal is to see if the pill-only option works as well as chemo while being less toxic and more convenient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200230, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.